![]()
![]()
近几年来，肿瘤新生抗原（neoantigens）成为了肿瘤免疫治疗领域中的一个新兴研究方向。有研究显示，新生抗原在免疫检查点抑制剂疗法、过继性T细胞治疗、治疗性肿瘤疫苗的开发应用等方面具有特殊价值，它为精准治疗恶性肿瘤带来了新的希望，成为抗癌“黑科技”之一。
本期，我们邀请到肿瘤免疫疗法开发企业康德赛的负责人丁平博士，围绕肿瘤新抗原的发展脉络、相关疗法开发、未来可能面临的挑战等进行领域介绍和观点分享。
![]()
![]()
丁平，四川康德赛医疗科技有限公司（以下简称“康德赛”）CEO，四川大学生命科学学院硕士毕业，2006年赴德国攻读博士学位，后在德国工作数年，回国后进入莱美药业担任重大项目部总监，负责国外产品、技术引进和对外投资。自2006年康德赛成立，成为公司负责人，专注于个性化肿瘤免疫疗法——肿瘤新抗原，开发肿瘤新药。
</section><p><img class="rich_pages wxw-img" data-ratio="0.12522686025408347" data-src="https://mmbiz.qpic.cn/mmbiz_png/lnBicB8p160ZPQnAQM4SInpylMysfVtmIHRo9Zl3Na459dutTeXqUIsRibHvKMicBianicoryOZCtxOPF3eEc24rvtQ/640?wx_fmt=png" data-type="png" data-w="551" style="box-sizing: border-box;max-inline-size: 100%;margin: 0px;padding: 0px;cursor: pointer;color: rgb(0, 0, 0);font-size: 17px;caret-color: rgb(255, 0, 0);text-align: center;background-color: rgb(255, 255, 255);vertical-align: inherit;width: 100%;max-width: 100% !important;overflow-wrap: break-word !important;outline: none 0px !important;height: auto !important;font-family: 微软雅黑, sans-serif;"/></p></section><section auto="" border-box="" data-id="119093" data-tools="135编辑器" https:="" repeat="" style="padding: 0px;background-image: url("><section style="margin: 10px auto;transform-style: preserve-3d;"><section style="display: flex;justify-content: flex-start;margin: 0 0 -7px 0;transform: translateZ(10px);-webkit-transform: translateZ(10px);-moz-transform: translateZ(10px);-ms-transform: translateZ(10px);-o-transform: translateZ(10px);"><section style="background-color: #ffffff;padding: 0px 5px 0px 0px;box-sizing: border-box;"><section style="box-sizing:border-box;width: 20px;"><svg style="display: block;" viewbox="0 0 28 23" xml:space="default" xmlns="http://www.w3.org/2000/svg"><g><g><path d="M15.5,2.61A2.1,2.1,0,0,1,17.61.5h7.78A2.1,2.1,0,0,1,27.5,2.61v7.78a2.1,2.1,0,0,1-2.11,2.11H19.76a8,8,0,0,0,7.74,6v4a12,12,0,0,1-12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/><path d="M.5,2.61A2.1,2.1,0,0,1,2.61.5h7.78A2.1,2.1,0,0,1,12.5,2.61v7.78a2.1,2.1,0,0,1-2.11,2.11H4.76a8,8,0,0,0,7.74,6v4a12,12,0,0,1-12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/></g></g></svg></section></section></section><section style="border-color: rgb(12, 137, 24) rgb(12, 137, 24) rgb(12, 137, 24) currentcolor;border-style: dashed dashed dashed none;border-width: 1px 1px 1px medium;padding: 10px 10px 10px 0px;transform: translateZ(5px);"><section data-autoskip="1" style="text-align: justify;line-height:1.75em;letter-spacing: 1.5px;font-size:14px;color:#515c63;background: transparent;"><p><span style="font-size: 15px;font-family: Helvetica, Arial, sans-serif;"><strong><span style="font-size: 15px;color: rgb(16, 122, 73);font-family: Helvetica, Arial, sans-serif;"><em><span style="font-size: 15px;caret-color: rgb(255, 0, 0);display: inline !important;font-family: Helvetica, Arial, sans-serif;">Bio Collaborate：</span></em></span></strong><span style="font-size: 15px;color: rgb(16, 122, 73);font-family: Helvetica, Arial, sans-serif;"><em><span style="font-size: 15px;caret-color: rgb(255, 0, 0);display: inline !important;font-family: Helvetica, Arial, sans-serif;">近两年，肿瘤新抗原疗法发展迅速，您能简要介绍一下新抗原这一新兴肿瘤治疗手段吗？</span></em></span></span></p></section></section><section style="border-color: currentcolor currentcolor rgb(12, 137, 24) rgb(12, 137, 24);border-style: none none dashed dashed;border-width: medium medium 1px 1px;padding: 10px 0px 10px 10px;transform: translateZ(5px);"><section data-width="100%" style="box-sizing:border-box;max-width: 100% !important;width: 100%;"><p style="line-height: 1.5em;"><span style="font-family: Helvetica, Arial, sans-serif;"><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;">肿瘤新抗原早在1988年就被研究人员所发现，但那时基因测序技术还未得到充分发展，也没有形成完整的基因测序产业链来为科学研究提供充足技术支持。</span><span style="background-color: rgb(254, 236, 175);font-family: Helvetica, Arial, sans-serif;"><strong><span style="font-size: 14px;color: rgb(73, 68, 41);background-color: rgb(254, 236, 175);font-family: Helvetica, Arial, sans-serif;">直至二十一世纪初，人类基因组草图绘制完成并发布，今年5月Science期刊同时发表了六篇文章，介绍了国际科研团队对人类基因组进行完整的、无间隙测序，把基因组中超过8%的Gap补充起来。</span></strong></span></span></p><p style="line-height: 1.5em;"><br/></p><p style="line-height: 1.5em;"><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;">在大量人力物力和技术的支持下，人类基因组的测序达到了前所未有的完整程度。今天，我们的基因测序技术已经发展的非常成熟，成本低且效率高。在测序技术的高速发展下，科学家们发现肿瘤与正常细胞的相异是由基因突变引起。对于我们所说的肿瘤新抗原，在它们发生的基因变异中，</span><strong><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;">90%以上是点突变，其他则是一些插入、错位和重组的突变情况。</span></strong><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;">因此，新生抗原只在肿瘤细胞上被表达，而正常细胞上是没有的，这赋予了基于肿瘤新抗原开发的治疗方法安全性非常好。</span></p></section></section><section style="display: flex;justify-content: flex-end;margin: -7px 0 0 0;transform: translateZ(10px);-webkit-transform: translateZ(10px);-moz-transform: translateZ(10px);-ms-transform: translateZ(10px);-o-transform: translateZ(10px);"><section style="background-color: #ffffff;padding: 0px 0px 0px 5px;box-sizing: border-box;"><section style="box-sizing:border-box;width: 20px;"><svg style="display: block;" viewbox="0 0 28 23" xml:space="default" xmlns="http://www.w3.org/2000/svg"><g><g><path d="M12.5,2.61A2.1,2.1,0,0,0,10.39.5H2.61A2.1,2.1,0,0,0,.5,2.61v7.78A2.1,2.1,0,0,0,2.61,12.5H8.24a8,8,0,0,1-7.74,6v4a12,12,0,0,0,12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/><path d="M27.5,2.61A2.1,2.1,0,0,0,25.39.5H17.61A2.1,2.1,0,0,0,15.5,2.61v7.78a2.1,2.1,0,0,0,2.11,2.11h5.63a8,8,0,0,1-7.74,6v4a12,12,0,0,0,12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/></g></g></svg></section></section></section></section></section><p style="line-height:2em;"><img data-ratio="0.665625" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/lnBicB8p160ZPQnAQM4SInpylMysfVtmIej9nnnpw8q1gPHibmAKNIQyMicnef2RpxSzyiaWEsO0grvAMIeW2WPp5g/640?wx_fmt=jpeg" data-type="jpeg" data-w="640" style="max-width: 100% !important;box-sizing:border-box;vertical-align: inherit;width: 100%;"/></p><section auto="" border-box="" data-id="119093" data-tools="135编辑器" https:="" repeat="" style="padding: 0px;background-image: url("><section style="margin: 10px auto;transform-style: preserve-3d;"><section style="display: flex;justify-content: flex-start;margin: 0 0 -7px 0;transform: translateZ(10px);-webkit-transform: translateZ(10px);-moz-transform: translateZ(10px);-ms-transform: translateZ(10px);-o-transform: translateZ(10px);"><section style="background-color: #ffffff;padding: 0px 5px 0px 0px;box-sizing: border-box;"><section style="box-sizing:border-box;width: 20px;"><svg style="display: block;" viewbox="0 0 28 23" xml:space="default" xmlns="http://www.w3.org/2000/svg"><g><g><path d="M15.5,2.61A2.1,2.1,0,0,1,17.61.5h7.78A2.1,2.1,0,0,1,27.5,2.61v7.78a2.1,2.1,0,0,1-2.11,2.11H19.76a8,8,0,0,0,7.74,6v4a12,12,0,0,1-12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/><path d="M.5,2.61A2.1,2.1,0,0,1,2.61.5h7.78A2.1,2.1,0,0,1,12.5,2.61v7.78a2.1,2.1,0,0,1-2.11,2.11H4.76a8,8,0,0,0,7.74,6v4a12,12,0,0,1-12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/></g></g></svg></section></section></section><section style="border-color: rgb(12, 137, 24) rgb(12, 137, 24) rgb(12, 137, 24) currentcolor;border-style: dashed dashed dashed none;border-width: 1px 1px 1px medium;padding: 10px 10px 10px 0px;transform: translateZ(5px);"><section data-autoskip="1" style="text-align: justify;line-height:1.75em;letter-spacing: 1.5px;font-size:14px;color:#515c63;background: transparent;"><p><span style="font-size: 15px;font-family: Helvetica, Arial, sans-serif;"><strong><span style="font-size: 15px;color: rgb(16, 122, 73);font-family: Helvetica, Arial, sans-serif;"><em><span style="font-size: 15px;caret-color: rgb(255, 0, 0);display: inline !important;font-family: Helvetica, Arial, sans-serif;">Bio Collaborate：</span></em></span></strong><span style="font-size: 15px;color: rgb(16, 122, 73);font-family: Helvetica, Arial, sans-serif;"><em><span style="font-size: 15px;caret-color: rgb(255, 0, 0);display: inline !important;font-family: Helvetica, Arial, sans-serif;">为什么这两年肿瘤新抗原热度急剧攀升？</span></em></span></span></p></section></section><section style="border-color: currentcolor currentcolor rgb(12, 137, 24) rgb(12, 137, 24);border-style: none none dashed dashed;border-width: medium medium 1px 1px;padding: 10px 0px 10px 10px;transform: translateZ(5px);"><section data-width="100%" style="box-sizing:border-box;max-width: 100% !important;width: 100%;"><p style="line-height: 1.5em;"><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;">在2014年左右，Science、Nature等国际学术影响力较高的刊物连续刊登了多篇以肿瘤新抗原为靶点的临床研究论文，且试验结果都显现出非常好的治疗效果，安全性和可靠性相对较高。在这一趋势的推动下，近年来，大约过百篇有关肿瘤新抗原的文献被发表，涉及科学研究和临床研究两方面。比如，我们原来认为脑胶质瘤是恶性肿瘤中恶性程度最高的，因为身患这种肿瘤的病人五年成活率不超过10%，但在2018年，有文献报道了针对脑胶质瘤的新生抗原研究，临床结果显示出优越的疗效，PFS（从随机化到病人出现肿瘤进展或死亡的时间）和OS（从随机化开始到因各种原因导致病人死亡之间的时间）都是远远超过了现有药物治疗的水平。</span></p><p style="line-height: 1.5em;"><br/></p><p style="line-height: 1.5em;"><span style="font-family: Helvetica, Arial, sans-serif;"><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;">现下，就肿瘤新抗原为靶点开发的新药进入二期的临床非常多，大家也可以看一些国际生物技术公司对肿瘤新抗原疫苗的青睐</span><span style="color: rgb(89, 89, 89);background-color: rgb(254, 236, 175);font-family: Helvetica, Arial, sans-serif;"><span style="color: rgb(89, 89, 89);font-size: 14px;background-color: rgb(254, 236, 175);font-family: Helvetica, Arial, sans-serif;">，</span><strong><span style="color: rgb(89, 89, 89);font-size: 14px;background-color: rgb(254, 236, 175);font-family: Helvetica, Arial, sans-serif;">如BioNTech在近两个月提出肿瘤疫苗有可能将在2030年问世。</span></strong></span><span style="color: rgb(12, 137, 24);font-family: Helvetica, Arial, sans-serif;"><strong><span style="font-size: 14px;font-family: Helvetica, Arial, sans-serif;"/></strong><strong><span style="font-size: 14px;font-family: Helvetica, Arial, sans-serif;"/></strong></span><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;">此外以Moderna为代表的业内龙头也布局了多个对于肿瘤新生抗原管线，正进行着临床实验。</span></span></p></section></section><section style="display: flex;justify-content: flex-end;margin: -7px 0 0 0;transform: translateZ(10px);-webkit-transform: translateZ(10px);-moz-transform: translateZ(10px);-ms-transform: translateZ(10px);-o-transform: translateZ(10px);"><section style="background-color: #ffffff;padding: 0px 0px 0px 5px;box-sizing: border-box;"><section style="box-sizing:border-box;width: 20px;"><svg style="display: block;" viewbox="0 0 28 23" xml:space="default" xmlns="http://www.w3.org/2000/svg"><g><g><path d="M12.5,2.61A2.1,2.1,0,0,0,10.39.5H2.61A2.1,2.1,0,0,0,.5,2.61v7.78A2.1,2.1,0,0,0,2.61,12.5H8.24a8,8,0,0,1-7.74,6v4a12,12,0,0,0,12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/><path d="M27.5,2.61A2.1,2.1,0,0,0,25.39.5H17.61A2.1,2.1,0,0,0,15.5,2.61v7.78a2.1,2.1,0,0,0,2.11,2.11h5.63a8,8,0,0,1-7.74,6v4a12,12,0,0,0,12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/></g></g></svg></section></section></section></section></section><p style="line-height:2em;"><img class="rich_pages wxw-img" data-ratio="0.5583333333333333" data-src="https://mmbiz.qpic.cn/mmbiz/lnBicB8p160ZPQnAQM4SInpylMysfVtmI0Zp5pRg0x4YKOm1zxEKxVOfbu61iakJ5V7rKZ3QLfASwgPkr1c6Inrg/640?wx_fmt=other" data-type="other" data-w="720" style="max-width: 100% !important;box-sizing:border-box;vertical-align: inherit;width: 100%;"/></p><section auto="" border-box="" data-id="119093" data-tools="135编辑器" https:="" repeat="" style="padding: 0px;background-image: url("><section style="margin: 10px auto;transform-style: preserve-3d;"><section style="display: flex;justify-content: flex-start;margin: 0 0 -7px 0;transform: translateZ(10px);-webkit-transform: translateZ(10px);-moz-transform: translateZ(10px);-ms-transform: translateZ(10px);-o-transform: translateZ(10px);"><section style="background-color: #ffffff;padding: 0px 5px 0px 0px;box-sizing: border-box;"><section style="box-sizing:border-box;width: 20px;"><svg style="display: block;" viewbox="0 0 28 23" xml:space="default" xmlns="http://www.w3.org/2000/svg"><g><g><path d="M15.5,2.61A2.1,2.1,0,0,1,17.61.5h7.78A2.1,2.1,0,0,1,27.5,2.61v7.78a2.1,2.1,0,0,1-2.11,2.11H19.76a8,8,0,0,0,7.74,6v4a12,12,0,0,1-12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/><path d="M.5,2.61A2.1,2.1,0,0,1,2.61.5h7.78A2.1,2.1,0,0,1,12.5,2.61v7.78a2.1,2.1,0,0,1-2.11,2.11H4.76a8,8,0,0,0,7.74,6v4a12,12,0,0,1-12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/></g></g></svg></section></section></section><section style="border-color: rgb(12, 137, 24) rgb(12, 137, 24) rgb(12, 137, 24) currentcolor;border-style: dashed dashed dashed none;border-width: 1px 1px 1px medium;padding: 10px 10px 10px 0px;transform: translateZ(5px);"><section data-autoskip="1" style="text-align: justify;line-height:1.75em;letter-spacing: 1.5px;font-size:14px;color:#515c63;background: transparent;"><p><span style="font-size: 15px;font-family: Helvetica, Arial, sans-serif;"><strong><span style="font-size: 15px;color: rgb(16, 122, 73);font-family: Helvetica, Arial, sans-serif;"><em><span style="font-size: 15px;caret-color: rgb(255, 0, 0);display: inline !important;font-family: Helvetica, Arial, sans-serif;">Bio Collaborate：</span></em></span></strong><span style="font-size: 15px;color: rgb(16, 122, 73);font-family: Helvetica, Arial, sans-serif;"><em><span style="font-size: 15px;caret-color: rgb(255, 0, 0);display: inline !important;font-family: Helvetica, Arial, sans-serif;">在未来的研究或全面向市场铺开的过程中，肿瘤新抗原疗法将会面临哪些挑战？</span></em></span></span></p></section></section><section style="border-color: currentcolor currentcolor rgb(12, 137, 24) rgb(12, 137, 24);border-style: none none dashed dashed;border-width: medium medium 1px 1px;padding: 10px 0px 10px 10px;transform: translateZ(5px);"><section data-width="100%" style="box-sizing:border-box;max-width: 100% !important;width: 100%;"><p style="line-height: 1.5em;"><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;">这一过程确实存在着几个大的挑战：</span></p><p style="line-height: 1.5em;"><br/></p><p style="line-height: 1.5em;"><strong><span style="font-size: 14px;background-color: rgb(254, 236, 175);color: rgb(89, 89, 89);font-family: Helvetica, Arial, sans-serif;">第一，如何更加精准地预测有效的肿瘤新抗原，还需从科学角度进一步做考虑。</span></strong><span style="font-family: Helvetica, Arial, sans-serif;"><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;">从突变的角度来讲，我们可以在一个肿瘤病人的基因中找到非常多的突变，但其中仅有1%的突变能成为一个我们所谓的新抗原。去年，国际上肿瘤新抗原的预测联盟团体在Cell期刊上发文，提到了当下对新抗原的预测准确性还不足50%。因此，</span><strong><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;">如何用科学的算法快速验证是否获得的抗原是有用的，提高我们肿瘤新生抗原的预测准确性，将是未来持续要解决的问题。</span></strong></span></p><p style="text-align:center;line-height: 1.5em;"><span style="font-family: Helvetica, Arial, sans-serif;"><strong><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;"><img data-ratio="0.6675925925925926" data-src="https://mmbiz.qpic.cn/mmbiz_png/lnBicB8p160ZPQnAQM4SInpylMysfVtmI0QpiaFchq4TDxwOsibEDicq7fb7XKiao8365yGNWpOfVvd4qoVlicSmvH8Q/640?wx_fmt=png" data-type="png" data-w="1080" data-width="435px" style="box-sizing: border-box;max-inline-size: 100%;margin: 0px;padding: 0px;cursor: pointer;color: rgb(0, 0, 0);font-size: 17px;caret-color: rgb(255, 0, 0);background-color: rgb(255, 255, 255);vertical-align: inherit;width: 435px;overflow-wrap: break-word !important;outline: none 0px !important;font-family: 微软雅黑, sans-serif;" width="435"/></span></strong></span></p><p style="line-height: 1.5em;"><span style="color: #595959;background-color: #feecaf;"><strong><span style="color: rgb(89, 89, 89);font-size: 14px;background-color: rgb(254, 236, 175);font-family: Helvetica, Arial, sans-serif;">第二，个性化且疗效显著的精准治疗，往往意味着高昂的成本，肿瘤新抗原疗法如何降低成本，提高制备速度，也是目前的挑战之一。</span></strong></span><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;">在肿瘤新抗原寻找的过程中，我们需要对每一个病人的肿瘤细胞进行深度测序和个性化分析。由于这种新抗原普遍存在于90%以上的癌肿中，所以它对癌肿来讲具有普遍性。</span></p></section></section><section style="display: flex;justify-content: flex-end;margin: -7px 0 0 0;transform: translateZ(10px);-webkit-transform: translateZ(10px);-moz-transform: translateZ(10px);-ms-transform: translateZ(10px);-o-transform: translateZ(10px);"><section style="background-color: #ffffff;padding: 0px 0px 0px 5px;box-sizing: border-box;"><section style="box-sizing:border-box;width: 20px;"><svg style="display: block;" viewbox="0 0 28 23" xml:space="default" xmlns="http://www.w3.org/2000/svg"><g><g><path d="M12.5,2.61A2.1,2.1,0,0,0,10.39.5H2.61A2.1,2.1,0,0,0,.5,2.61v7.78A2.1,2.1,0,0,0,2.61,12.5H8.24a8,8,0,0,1-7.74,6v4a12,12,0,0,0,12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/><path d="M27.5,2.61A2.1,2.1,0,0,0,25.39.5H17.61A2.1,2.1,0,0,0,15.5,2.61v7.78a2.1,2.1,0,0,0,2.11,2.11h5.63a8,8,0,0,1-7.74,6v4a12,12,0,0,0,12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/></g></g></svg></section></section></section></section></section><section data-role="paragraph"><p><br/></p></section><section data-id="93454" data-tools="135编辑器"><section style="display: flex;border-color: rgb(95, 95, 94);border-style: solid;border-width: 1px;box-shadow: rgb(90, 166, 50) 3px 3px 0px;border-radius: 10px;margin: 10px 5px 5px auto;box-sizing: border-box;"><section data-width="10%" style="max-width:10% !important;box-sizing:border-box;margin-top:14px;margin-left:10px;width:10%;"><img data-ratio="0.8073394495412844" data-src="https://mmbiz.qpic.cn/mmbiz_png/ldFaBNSkvHhfReibVrfKgxN97qcFx3LVvHmfTYU065P2GNVC8FhTh123NyMjcicJiaK6Xt2AjTQIX0ps3iaUiaNVRibQ/640?wx_fmt=png" data-w="109" data-width="100%" style="max-width:100% !important;box-sizing:border-box;vertical-align:inherit;width:100%;"/></section><section data-width="90%" style="max-width:90% !important;box-sizing:border-box;width:90%;font-size: 14px;color: #3f3f3f;letter-spacing: 1.5px;padding: 1em 0.8em;display:inlne-block;text-align:justify;"><section><p><span style="font-family: Helvetica, Arial, sans-serif;"><em><span style="color: rgb(73, 68, 41);font-size: 14px;caret-color: rgb(255, 0, 0);display: inline !important;font-family: Helvetica, Arial, sans-serif;">在最理想的情况下，找到一个相对来说共有的肿瘤新抗原，比如在100个患者中能有10个患者有共同的新抗原，那么肿瘤新抗原就可以从一个单一个体的个体化的治疗变成一个现货型的团体治疗手段。这个也是我们未来一直探索的方向。”</span></em></span></p></section></section></section></section><p style="line-height:2em;"><br/></p><p style="line-height:2em;"><br/></p><p style="line-height:2em;"><img class="rich_pages wxw-img" data-ratio="0.4601851851851852" data-src="https://mmbiz.qpic.cn/mmbiz_png/lnBicB8p160ZPQnAQM4SInpylMysfVtmI5q2yibQfwOcz1ZbEibibztfUeF54fYlzmb47krFoRG47RuDUZjKBxuU8w/640?wx_fmt=png" data-type="png" data-w="1080" style="box-sizing: border-box;max-inline-size: 100%;margin: 0px;padding: 0px;cursor: pointer;color: rgb(0, 0, 0);font-size: 17px;caret-color: rgb(255, 0, 0);background-color: rgb(255, 255, 255);vertical-align: inherit;width: 100%;max-width: 100% !important;overflow-wrap: break-word !important;outline: none 0px !important;height: auto !important;font-family: 微软雅黑, sans-serif;"/></p><section auto="" border-box="" data-id="119093" data-tools="135编辑器" https:="" repeat="" style="padding: 0px;background-image: url("><section style="margin: 10px auto;transform-style: preserve-3d;"><section style="display: flex;justify-content: flex-start;margin: 0 0 -7px 0;transform: translateZ(10px);-webkit-transform: translateZ(10px);-moz-transform: translateZ(10px);-ms-transform: translateZ(10px);-o-transform: translateZ(10px);"><section style="background-color: #ffffff;padding: 0px 5px 0px 0px;box-sizing: border-box;"><section style="box-sizing:border-box;width: 20px;"><svg style="display: block;" viewbox="0 0 28 23" xml:space="default" xmlns="http://www.w3.org/2000/svg"><g><g><path d="M15.5,2.61A2.1,2.1,0,0,1,17.61.5h7.78A2.1,2.1,0,0,1,27.5,2.61v7.78a2.1,2.1,0,0,1-2.11,2.11H19.76a8,8,0,0,0,7.74,6v4a12,12,0,0,1-12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/><path d="M.5,2.61A2.1,2.1,0,0,1,2.61.5h7.78A2.1,2.1,0,0,1,12.5,2.61v7.78a2.1,2.1,0,0,1-2.11,2.11H4.76a8,8,0,0,0,7.74,6v4a12,12,0,0,1-12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/></g></g></svg></section></section></section><section style="border-color: rgb(12, 137, 24) rgb(12, 137, 24) rgb(12, 137, 24) currentcolor;border-style: dashed dashed dashed none;border-width: 1px 1px 1px medium;padding: 10px 10px 10px 0px;transform: translateZ(5px);"><section data-autoskip="1" style="text-align: justify;line-height:1.75em;letter-spacing: 1.5px;font-size:14px;color:#515c63;background: transparent;"><p><span style="font-size: 15px;font-family: Helvetica, Arial, sans-serif;"><strong><span style="font-size: 15px;color: rgb(16, 122, 73);font-family: Helvetica, Arial, sans-serif;"><em><span style="font-size: 15px;caret-color: rgb(255, 0, 0);display: inline !important;font-family: Helvetica, Arial, sans-serif;">Bio Collaborate：</span></em></span></strong><span style="font-size: 15px;color: rgb(16, 122, 73);font-family: Helvetica, Arial, sans-serif;"><em><span style="font-size: 15px;caret-color: rgb(255, 0, 0);display: inline !important;font-family: Helvetica, Arial, sans-serif;">目前，越来越多的企业进入赛道，康德赛的优势是什么？</span></em></span></span></p></section></section><section style="border-color: currentcolor currentcolor rgb(12, 137, 24) rgb(12, 137, 24);border-style: none none dashed dashed;border-width: medium medium 1px 1px;padding: 10px 0px 10px 10px;transform: translateZ(5px);"><section data-width="100%" style="box-sizing:border-box;max-width: 100% !important;width: 100%;"><p style="line-height: 1.5em;"><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;">首先，康德赛在2016年创立伊始，就选择了</span><span style="background-color: #feecaf;color: #3f3151;"><strong><span style="font-size: 14px;background-color: rgb(254, 236, 175);font-family: Helvetica, Arial, sans-serif;">mRNA编辑细胞</span></strong></span><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;">这条技术路线。那时，mRNA还是一个非常冷门的小众成药体系，基于我们本身对mRNA和核苷酸修饰研究的积累，我们相信mRNA在未来不管从成药的安全性，还是从成药的有效性，都是一项潜力十足的技术手段，走到今天我们建立的成药平台具有一定的先进性。</span></p><p style="line-height: 1.5em;"><img class="rich_pages wxw-img" data-ratio="0.4381395348837209" data-src="https://mmbiz.qpic.cn/mmbiz_png/lnBicB8p160ZPQnAQM4SInpylMysfVtmIa3v5IPD0Boia47ibWPO17Liavdp8vbpFxEutxSrFu7C7dqlKOibJuHv1LQ/640?wx_fmt=png" data-type="png" data-w="1075" style="box-sizing: border-box;max-inline-size: 100%;margin: 0px;padding: 0px;cursor: pointer;color: rgb(0, 0, 0);font-size: 17px;caret-color: rgb(255, 0, 0);background-color: rgb(255, 255, 255);vertical-align: inherit;width: 100%;max-width: 100% !important;overflow-wrap: break-word !important;outline: none 0px !important;height: auto !important;font-family: 微软雅黑, sans-serif;"/></p><p style="line-height: 1.5em;"><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;">第二，</span><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;text-decoration: underline;">跟国内大部分mRNA企业相比，我们还建有独立自主的细胞平台，mRNA技术与细胞平台的结合，能够帮助规避现有mRNA存在的缺陷，充分发挥mRNA的成药能力。</span><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;">因为mRNA可以在胞内胞外表达，同时作用的靶点分布广泛。但它脆弱且敏感，易被体内环境降解，所以我们看到国外现在做成药的公司都会用一些特殊的包裹物来提高其稳定性。另外，mRNA具有外源性，也可通过细胞平台的处理来避开人体的强免疫机制，弱化mRNA的弱点以发挥其优秀的治疗作用。</span></p></section></section><section style="display: flex;justify-content: flex-end;margin: -7px 0 0 0;transform: translateZ(10px);-webkit-transform: translateZ(10px);-moz-transform: translateZ(10px);-ms-transform: translateZ(10px);-o-transform: translateZ(10px);"><section style="background-color: #ffffff;padding: 0px 0px 0px 5px;box-sizing: border-box;"><section style="box-sizing:border-box;width: 20px;"><svg style="display: block;" viewbox="0 0 28 23" xml:space="default" xmlns="http://www.w3.org/2000/svg"><g><g><path d="M12.5,2.61A2.1,2.1,0,0,0,10.39.5H2.61A2.1,2.1,0,0,0,.5,2.61v7.78A2.1,2.1,0,0,0,2.61,12.5H8.24a8,8,0,0,1-7.74,6v4a12,12,0,0,0,12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/><path d="M27.5,2.61A2.1,2.1,0,0,0,25.39.5H17.61A2.1,2.1,0,0,0,15.5,2.61v7.78a2.1,2.1,0,0,0,2.11,2.11h5.63a8,8,0,0,1-7.74,6v4a12,12,0,0,0,12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/></g></g></svg></section></section></section></section></section><p style="line-height:2em;"><br/></p><section auto="" border-box="" data-id="119093" data-tools="135编辑器" https:="" repeat="" style="padding: 0px;background-image: url("><section style="margin: 10px auto;transform-style: preserve-3d;"><section style="display: flex;justify-content: flex-start;margin: 0 0 -7px 0;transform: translateZ(10px);-webkit-transform: translateZ(10px);-moz-transform: translateZ(10px);-ms-transform: translateZ(10px);-o-transform: translateZ(10px);"><section style="background-color: #ffffff;padding: 0px 5px 0px 0px;box-sizing: border-box;"><section style="box-sizing:border-box;width: 20px;"><svg style="display: block;" viewbox="0 0 28 23" xml:space="default" xmlns="http://www.w3.org/2000/svg"><g><g><path d="M15.5,2.61A2.1,2.1,0,0,1,17.61.5h7.78A2.1,2.1,0,0,1,27.5,2.61v7.78a2.1,2.1,0,0,1-2.11,2.11H19.76a8,8,0,0,0,7.74,6v4a12,12,0,0,1-12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/><path d="M.5,2.61A2.1,2.1,0,0,1,2.61.5h7.78A2.1,2.1,0,0,1,12.5,2.61v7.78a2.1,2.1,0,0,1-2.11,2.11H4.76a8,8,0,0,0,7.74,6v4a12,12,0,0,1-12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/></g></g></svg></section></section></section><section style="border-color: rgb(12, 137, 24) rgb(12, 137, 24) rgb(12, 137, 24) currentcolor;border-style: dashed dashed dashed none;border-width: 1px 1px 1px medium;padding: 10px 10px 10px 0px;transform: translateZ(5px);"><section data-autoskip="1" style="text-align: justify;line-height:1.75em;letter-spacing: 1.5px;font-size:14px;color:#515c63;background: transparent;"><p><span style="font-size: 15px;font-family: Helvetica, Arial, sans-serif;"><strong><span style="font-size: 15px;color: rgb(16, 122, 73);font-family: Helvetica, Arial, sans-serif;"><em><span style="font-size: 15px;caret-color: rgb(255, 0, 0);display: inline !important;font-family: Helvetica, Arial, sans-serif;">Bio Collaborate：</span></em></span></strong><span style="font-size: 15px;color: rgb(16, 122, 73);font-family: Helvetica, Arial, sans-serif;"><em><span style="font-size: 15px;caret-color: rgb(255, 0, 0);display: inline !important;font-family: Helvetica, Arial, sans-serif;">有国内企业以AI赋能基于mRNA技术的肿瘤新抗原疗法管线，您如何看待这类IT&BT融合对研发工作的助力？</span></em></span></span></p></section></section><section style="border-color: currentcolor currentcolor rgb(12, 137, 24) rgb(12, 137, 24);border-style: none none dashed dashed;border-width: medium medium 1px 1px;padding: 10px 0px 10px 10px;transform: translateZ(5px);"><section data-width="100%" style="box-sizing:border-box;max-width: 100% !important;width: 100%;"><p style="line-height: 1.5em;"><span style="font-family: Helvetica, Arial, sans-serif;"><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;">无论是AI的技术也好，还是传统的算法，都需要大量数据来不断纠正和训练。但就肿瘤新抗原来说，从国际报道的有效mRNA新生抗原的数目过少，且个体化程度相当高，训练集过小。要让AI工具进行精准判断的关键前提是我们要知道什么是正确的，什么是错误的，这样才能科学地训练算法。这也意味着，这些AI技术公司需要有一套验证的方法和工具去对真实的情况进行判定。在国外关于AI+肿瘤新抗原研究的企业报道还是比较少的，因为这需要企业本身积累有一定量的正确数据和错误数据，来反复锻造AI系统，这样才能提升新抗原预测软件的准确性。</span></span></p><p style="line-height: 1.5em;"><br/></p><p style="line-height: 1.5em;"><span style="font-family: Helvetica, Arial, sans-serif;"><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;">现阶段，虽然海量训练集还没有实现，但是AI肯定是未来的大方向，随着新生抗原的数量不断增加，相应的数据也将持续增长，未来肯定会有更多AI能够充分发挥优势的节点。其实，</span><span style="color: rgb(89, 89, 89);background-color: rgb(254, 236, 175);font-family: Helvetica, Arial, sans-serif;"><strong><span style="color: rgb(89, 89, 89);font-size: 14px;background-color: rgb(254, 236, 175);font-family: Helvetica, Arial, sans-serif;">新抗原本身就是需要IT和BT相互结合的一个领域，既需要一支信息团队反复锤炼算法，还需要一支生物的团队不断提供实验的数据来验证。</span></strong></span><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;">我觉得未来的新抗原的公司必须具有这两方面的能力，才能真正实现新抗原预测的准确性和有效性。</span></span></p></section></section><section style="display: flex;justify-content: flex-end;margin: -7px 0 0 0;transform: translateZ(10px);-webkit-transform: translateZ(10px);-moz-transform: translateZ(10px);-ms-transform: translateZ(10px);-o-transform: translateZ(10px);"><section style="background-color: #ffffff;padding: 0px 0px 0px 5px;box-sizing: border-box;"><section style="box-sizing:border-box;width: 20px;"><svg style="display: block;" viewbox="0 0 28 23" xml:space="default" xmlns="http://www.w3.org/2000/svg"><g><g><path d="M12.5,2.61A2.1,2.1,0,0,0,10.39.5H2.61A2.1,2.1,0,0,0,.5,2.61v7.78A2.1,2.1,0,0,0,2.61,12.5H8.24a8,8,0,0,1-7.74,6v4a12,12,0,0,0,12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/><path d="M27.5,2.61A2.1,2.1,0,0,0,25.39.5H17.61A2.1,2.1,0,0,0,15.5,2.61v7.78a2.1,2.1,0,0,0,2.11,2.11h5.63a8,8,0,0,1-7.74,6v4a12,12,0,0,0,12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/></g></g></svg></section></section></section></section></section><p style="line-height:2em;"><img class="rich_pages wxw-img" data-ratio="0.6613247863247863" data-src="https://mmbiz.qpic.cn/mmbiz_png/lnBicB8p160ZPQnAQM4SInpylMysfVtmISTx7lVnULvGt0uaaz9uMumkEPNVq86OSMWBNyzm03icT1iaibEApUvahQ/640?wx_fmt=png" data-type="png" data-w="936" style="max-width: 100% !important;box-sizing:border-box;vertical-align: inherit;width: 100%;"/></p><section auto="" border-box="" data-id="119093" data-tools="135编辑器" https:="" repeat="" style="padding: 0px;background-image: url("><section style="margin: 10px auto;transform-style: preserve-3d;"><section style="display: flex;justify-content: flex-start;margin: 0 0 -7px 0;transform: translateZ(10px);-webkit-transform: translateZ(10px);-moz-transform: translateZ(10px);-ms-transform: translateZ(10px);-o-transform: translateZ(10px);"><section style="background-color: #ffffff;padding: 0px 5px 0px 0px;box-sizing: border-box;"><section style="box-sizing:border-box;width: 20px;"><svg style="display: block;" viewbox="0 0 28 23" xml:space="default" xmlns="http://www.w3.org/2000/svg"><g><g><path d="M15.5,2.61A2.1,2.1,0,0,1,17.61.5h7.78A2.1,2.1,0,0,1,27.5,2.61v7.78a2.1,2.1,0,0,1-2.11,2.11H19.76a8,8,0,0,0,7.74,6v4a12,12,0,0,1-12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/><path d="M.5,2.61A2.1,2.1,0,0,1,2.61.5h7.78A2.1,2.1,0,0,1,12.5,2.61v7.78a2.1,2.1,0,0,1-2.11,2.11H4.76a8,8,0,0,0,7.74,6v4a12,12,0,0,1-12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/></g></g></svg></section></section></section><section style="border-color: rgb(12, 137, 24) rgb(12, 137, 24) rgb(12, 137, 24) currentcolor;border-style: dashed dashed dashed none;border-width: 1px 1px 1px medium;padding: 10px 10px 10px 0px;transform: translateZ(5px);"><section data-autoskip="1" style="text-align: justify;line-height:1.75em;letter-spacing: 1.5px;font-size:14px;color:#515c63;background: transparent;"><p><span style="font-size: 15px;font-family: Helvetica, Arial, sans-serif;"><strong><span style="font-size: 15px;color: rgb(16, 122, 73);font-family: Helvetica, Arial, sans-serif;"><em><span style="font-size: 15px;caret-color: rgb(255, 0, 0);display: inline !important;font-family: Helvetica, Arial, sans-serif;">Bio Collaborate：</span></em></span></strong><span style="font-size: 15px;color: rgb(16, 122, 73);font-family: Helvetica, Arial, sans-serif;"><em><span style="font-size: 15px;caret-color: rgb(255, 0, 0);display: inline !important;font-family: Helvetica, Arial, sans-serif;">当前，现在康德赛的规模如何？作为目前国内鲜少几个有新抗原疗法IND正式被受理的公司之一，未来进一步的发展布局是怎样的？</span></em></span></span></p></section></section><section style="border-color: currentcolor currentcolor rgb(12, 137, 24) rgb(12, 137, 24);border-style: none none dashed dashed;border-width: medium medium 1px 1px;padding: 10px 0px 10px 10px;transform: translateZ(5px);"><section data-width="100%" style="box-sizing:border-box;max-width: 100% !important;width: 100%;"><p style="line-height: 1.5em;"><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;">我们现在有将近60多位同事，一半以上具有生物专业研究生学历。这支队伍中的人员都非常年轻，我们希望能从头手把手培养，让初入这个圈子的年轻人逐渐胜任康德赛的研发需求，并且青年人的活力、凝聚力、创造力也让我十分欣喜。</span></p><p style="line-height: 1.5em;"><br/></p><p style="line-height: 1.5em;"><span style="font-family: Helvetica, Arial, sans-serif;"><span style="color: rgb(16, 122, 73);font-family: Helvetica, Arial, sans-serif;"><strong><span style="font-size: 14px;font-family: Helvetica, Arial, sans-serif;">作为第一家使用mRNA作为工具来改造细胞产品的企业，在未来，康德赛还是会牢牢围绕mRNA和细胞的方向来进行产品开发。</span></strong></span></span></p><p style="line-height: 1.5em;"><span style="font-family: Helvetica, Arial, sans-serif;"><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;">一是我们会在现有产品的基础上不断做迭代和更新，扩展适应症；</span></span></p><p style="line-height: 1.5em;"><span style="font-family: Helvetica, Arial, sans-serif;"><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;">二是我们会进一步延伸自己的创造力，开发新的细胞平台产品，不仅限于新抗原，更要考虑如何充分利用康德赛早已具备的GMP生产能力，生产出价格可及、疗效优异的产品来治疗更多常见疾病或对价格非常敏感的一些疾病。</span></span></p><p style="line-height: 1.5em;"><br/></p><p style="line-height: 1.5em;"><span style="font-size: 14px;color: rgb(73, 68, 41);font-family: Helvetica, Arial, sans-serif;">未来，我们也希望以每年一个新案例的速度来推进公司新药的临床实验，也希望能够和大型药企达成战略合作关系，共同去推进某一类或某一种治疗癌肿的药物的临床实验，快速实现产品上市，让更多的患者能早日获益。</span></p></section></section><section style="display: flex;justify-content: flex-end;margin: -7px 0 0 0;transform: translateZ(10px);-webkit-transform: translateZ(10px);-moz-transform: translateZ(10px);-ms-transform: translateZ(10px);-o-transform: translateZ(10px);"><section style="background-color: #ffffff;padding: 0px 0px 0px 5px;box-sizing: border-box;"><section style="box-sizing:border-box;width: 20px;"><svg style="display: block;" viewbox="0 0 28 23" xml:space="default" xmlns="http://www.w3.org/2000/svg"><g><g><path d="M12.5,2.61A2.1,2.1,0,0,0,10.39.5H2.61A2.1,2.1,0,0,0,.5,2.61v7.78A2.1,2.1,0,0,0,2.61,12.5H8.24a8,8,0,0,1-7.74,6v4a12,12,0,0,0,12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/><path d="M27.5,2.61A2.1,2.1,0,0,0,25.39.5H17.61A2.1,2.1,0,0,0,15.5,2.61v7.78a2.1,2.1,0,0,0,2.11,2.11h5.63a8,8,0,0,1-7.74,6v4a12,12,0,0,0,12-12h0s0-.07,0-.11Z" style="fill:#fff;stroke:#0c8918;stroke-miterlimit:10;"/></g></g></svg></section></section></section></section></section><section data-id="94225" data-role="title" data-tools="135编辑器"><section style="padding: 1em 0px;box-sizing: border-box;"><section style="box-sizing:border-box;width:12em;margin: 0px auto;"><img data-ratio="0.20772946859903382" data-src="https://mmbiz.qpic.cn/mmbiz_gif/lnBicB8p160ZPQnAQM4SInpylMysfVtmIibOJtVRUcD2deZOAofAJN45kgRgv7BvkNu55lJ5DibMJoj8Yx9wsunuA/640?wx_fmt=gif" data-type="gif" data-w="1035" data-width="100%" style="max-width: 100% !important;box-sizing:border-box;vertical-align:inherit;width: 100%;display: block;"/></section></section></section><p><br/></p><p><img class="rich_pages wxw-img" data-ratio="0.6545454545454545" data-src="https://mmbiz.qpic.cn/mmbiz_png/lnBicB8p160ZPQnAQM4SInpylMysfVtmITmVzN8Jx0ZMEeQG9cxjoFb5EJFlggqUWxEEBiarOAmQZZwlgwCnUkmQ/640?wx_fmt=png" data-type="png" data-w="935" style="max-width: 100% !important;box-sizing:border-box;vertical-align: inherit;width: 100%;"/></p><section data-role="paragraph"><section data-role="paragraph" style="outline: 0px;max-width: 100%;visibility: visible;box-sizing: border-box !important;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;text-align: center;overflow-wrap: break-word !important;transform: translate3d(0px, 0px, 0px);"><section style="box-sizing:border-box;padding: 10px;outline: 0px;max-width: 100%;display: inline-block;width: 100%;height: 300px;vertical-align: top;overflow-y: auto;background-color: rgba(116, 164, 141, 0.17);overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-x: hidden;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;justify-content: center;display: flex;flex-flow: row nowrap;overflow-wrap: break-word !important;"><section style="box-sizing: border-box;outline: 0px;max-width: 100%;display: inline-block;vertical-align: middle;width: 14.939%;align-self: center;flex: 0 0 auto;overflow-wrap: break-word !important;"><section style="margin-top: 10px;margin-bottom: 5px;outline: 0px;max-width: 100%;box-sizing: border-box;line-height: 0.8;font-size: 10px;overflow-wrap: break-word !important;"><section style="box-sizing: border-box;outline: 0px;max-width: 100%;width: 0px;display: inline-block;border-bottom: 0.8em solid rgb(41, 120, 84);overflow-wrap: break-word !important;border-left: 0.7em solid transparent !important;border-right: 0.7em solid transparent !important;"><svg style="box-sizing:border-box;float:left;line-height:0;width:0;vertical-align:top;" viewbox="0 0 1 1" xml:space="default"/></section></section><section style="margin-top: 5px;margin-bottom: 10px;outline: 0px;max-width: 100%;box-sizing: border-box;line-height: 0.8;font-size: 10px;overflow-wrap: break-word !important;"><section style="box-sizing: border-box;outline: 0px;max-width: 100%;width: 0px;display: inline-block;border-top: 0.8em solid rgb(41, 120, 84);overflow-wrap: break-word !important;border-left: 0.7em solid transparent !important;border-right: 0.7em solid transparent !important;"><svg style="box-sizing:border-box;float:left;line-height:0;width:0;vertical-align:top;" viewbox="0 0 1 1" xml:space="default"/></section></section></section><section style="box-sizing:border-box;outline: 0px;max-width: 100%;display: inline-block;vertical-align: middle;width: 85.061%;align-self: center;flex: 0 0 auto;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 12px;color: #297854;text-align: left;letter-spacing: 1px;overflow-wrap: break-word !important;"><p style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><span style="font-family: Helvetica, Arial, sans-serif;"><em style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;">上下滑动查看</strong></em></span></p></section></section></section><section style="outline: 0px;max-width: 100%;box-sizing: border-box;text-align: justify;overflow-wrap: break-word !important;"><p style="outline: 0px;max-width: 100%;box-sizing: border-box;line-height: 1.5em;overflow-wrap: break-word !important;"><br/></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;margin-bottom: 5px;line-height: 2em;overflow-wrap: break-word !important;"><span style="font-family: Helvetica, Arial, sans-serif;"><em><span style="color: rgb(24, 94, 14);font-family: Helvetica, Arial, sans-serif;"><strong><span style="font-size: 19px;font-family: Helvetica, Arial, sans-serif;">四川康德赛医疗科技有限公司</span></strong></span></em><span style="font-size: 14px;color: rgb(127, 127, 127);font-family: Helvetica, Arial, sans-serif;">2016年11月07日成立于成都市高新区天府生命科技园，由多位留学归国科学家为核心团队，整合重庆莱美、北控医疗及华大基因等多家上市生物医药公司优势资源，借助国内外知名高校的雄厚科研力量，专注于恶性肿瘤、中晚期肝硬化等重大疾病的诊疗研究服务、产品开发的创新型生物医药企业。<br/></span></span></p></section><section style="outline: 0px;max-width: 100%;box-sizing: border-box;color: #646464;text-align: justify;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;line-height: 2em;box-sizing: border-box !important;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;line-height: 2em;box-sizing: border-box !important;overflow-wrap: break-word !important;"><p style="max-inline-size: 100%;margin: 0px 0px 5px;padding: 0px;clear: both;min-height: 1em;cursor: text;color: rgb(0, 0, 0);font-size: 17px;caret-color: rgb(255, 0, 0);line-height: 2em;box-sizing: border-box !important;overflow-wrap: break-word !important;outline: none 0px !important;font-family: 微软雅黑, sans-serif;"><span style="max-inline-size: 100%;margin: 0px;padding: 0px;cursor: text;font-size: 14px;color: rgb(127, 127, 127);box-sizing: border-box !important;overflow-wrap: break-word !important;outline: none 0px !important;font-family: Helvetica, Arial, sans-serif;">公司致力于新型细胞治疗技术在恶性肿瘤、中晚期肝硬化等人类重大疾病领域的开发、转化及应用。其自主研发的Cunde®技术平台是新一代个性化肿瘤疫苗开发平台。根据病人个体化的肿瘤新抗原，以自体树突状细胞为载体，提高人体免疫系统对于肿瘤细胞的识别性，提高肿瘤细胞的免疫原性和对效应细胞杀伤的敏感性，激发和增强机体抗肿瘤免疫应答；同时多维度调节肿瘤免疫微环境，协同机体免疫系统杀伤肿瘤，抑制肿瘤生长，减少肿瘤的复发。</span></p></section></section><section style="outline: 0px;max-width: 100%;line-height: 2em;box-sizing: border-box !important;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;font-size: 14px;letter-spacing: 2px;box-sizing: border-box !important;overflow-wrap: break-word !important;font-family: Helvetica, Arial, sans-serif;"/></section></section></section></section></section><section data-role="paragraph" style="outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;"><p><br/></p></section></section></section></section><section data-role="outer" label="edit by 135editor" style="margin-bottom: 0px;"><section data-role="outer" label="edit by 135editor" style="margin-bottom: 0px;"><section data-role="paragraph" style="margin-bottom: 0px;"><section data-role="paragraph"><section><section><section><p style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;text-align: center;"><strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"/><strong style="color: rgb(41, 120, 84);font-family: system-ui, -apple-system, BlinkMacSystemFont, Arial, sans-serif;font-size: 15px;letter-spacing: 3px;text-align: center;white-space: normal;background-color: rgb(255, 255, 255);outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;">>> END <<</strong><strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"/></p></section></section></section></section></section></section></section><section arial="" border-box="" break-word="" data-role="outer" gb="" helvetica="" label="edit by 135editor" neue="" rgb="" sans="" sans-serif="" sc="" style="white-space: normal;outline: 0px;max-width: 100%;color: rgb(34, 34, 34);font-family: system-ui, -apple-system, BlinkMacSystemFont, " ui="" visible="" yahei=""><section data-role="outer" label="edit by 135editor" style="margin-bottom: 24px;outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;"><section data-role="paragraph" style="outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;"><section data-role="outer" label="edit by 135editor" style="outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><p style="margin-right: 8px;margin-left: 8px;outline: 0px;max-width: 100%;box-sizing: border-box;line-height: 1.6em;text-align: right;overflow-wrap: break-word !important;"><img arial="" break-word="" class="rich_pages wxw-img" data-backh="93" data-backw="562" data-fileid="100039600" data-ratio="0.1666667" data-src="https://mmbiz.qpic.cn/mmbiz_png/lnBicB8p160ZKofw2MiaTPTj2jWV8ulkt9RPZX6JWZibXvd7Jp2cFvDqFnribLL82BuibzyE3yGhBdB8Zj5eBZkuP7w/640?wx_fmt=png&wxfrom=5&wx_lazy=1&wx_co=1" data-type="png" data-w="600" gb="" helvetica="" initial="" neue="" rgb="" sans="" sans-serif="" sc="" style="vertical-align: middle;outline: 0px;box-sizing: border-box;letter-spacing: 0.544px;text-align: justify;font-family: -apple-system, BlinkMacSystemFont, " ui="" visible="" width="657px" yahei=""/></p></section></section></section></section><section style="margin-bottom: 8px;outline: 0px;max-width: 100%;letter-spacing: 0.544px;box-sizing: border-box !important;overflow-wrap: break-word !important;"><a data-itemshowtype="0" data-linktype="1" href="http://mp.weixin.qq.com/s?__biz=MzUyMTU4ODg2MQ==&mid=2247536638&idx=1&sn=9fb35065e7eb1d2001cf0c8e9aaf267f&chksm=f9dad6eccead5ffa0ba6ce26aa9d9a3413549072accb88f3e19dbe222616c2d6a1c1bbd7da59&scene=21#wechat_redirect" imgdata="null" imgurl="" linktype="text" tab="innerlink" target="_blank" textvalue=""><span class="js_jump_icon h5_image_link" data-positionback="static" style="outline: 0px;max-width: 100%;line-height: 0;vertical-align: bottom;user-select: none;top: auto;left: auto;right: auto;bottom: auto;box-sizing: border-box !important;overflow-wrap: break-word !important;"><img class="rich_pages wxw-img" data-backh="129" data-backw="578" data-cropselx1="0" data-cropselx2="578" data-cropsely1="0" data-cropsely2="128" data-ratio="0.22282608695652173" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/lnBicB8p160bj0GhAkog2YoP3YSDNHZicnibM6qoFTz1AKgy8XzWEIDY5y18TOBlUswq49QicABku2qia5JdfDuGypA/640?wx_fmt=png" data-type="png" data-w="2208" style="outline: 0px;border-width: 0px;border-style: initial;border-color: initial;display: initial;width: 578px;box-sizing: border-box !important;overflow-wrap: break-word !important;visibility: visible !important;height: 129px;"/></span></a></section><section style="margin-bottom: 8px;outline: 0px;max-width: 100%;letter-spacing: 0.544px;box-sizing: border-box !important;overflow-wrap: break-word !important;"><a data-itemshowtype="0" data-linktype="1" href="http://mp.weixin.qq.com/s?__biz=MzUyMTU4ODg2MQ==&mid=2247536521&idx=1&sn=6de4c69c2913259316dfc62195cc0e38&chksm=f9dad69bcead5f8ddc64d061e6b13d46d21ca02867d22cd54568c60daea94472221671f01692&scene=21#wechat_redirect" imgdata="null" imgurl="" linktype="text" tab="innerlink" target="_blank" textvalue=""><span class="js_jump_icon h5_image_link" data-positionback="static" style="outline: 0px;max-width: 100%;line-height: 0;vertical-align: bottom;user-select: none;box-sizing: border-box !important;overflow-wrap: break-word !important;"><img class="rich_pages wxw-img" data-backh="129" data-backw="578" data-cropselx1="0" data-cropselx2="578" data-cropsely1="0" data-cropsely2="129" data-ratio="0.22282608695652173" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/lnBicB8p160bj0GhAkog2YoP3YSDNHZicnVm04XtdzicVggMedZzMEwPjW02px1icHR3WKiaPmw6c5l6kEdRK8PiaXibA/640?wx_fmt=png" data-type="png" data-w="2208" style="outline: 0px;border-width: 0px;border-style: initial;border-color: initial;display: initial;width: 578px;box-sizing: border-box !important;overflow-wrap: break-word !important;visibility: visible !important;height: 129px;"/></span></a></section><p style="margin-bottom: 0em;outline: 0px;max-width: 100%;letter-spacing: 0.544px;box-sizing: border-box !important;overflow-wrap: break-word !important;"><a data-itemshowtype="0" data-linktype="1" href="http://mp.weixin.qq.com/s?__biz=MzUyMTU4ODg2MQ==&mid=2247536638&idx=2&sn=10f6cba9c00145147b3ba2f72500a0f3&chksm=f9dad6eccead5ffa6c3d9844ad494b2d5427bb3ffabf46315078c53ada68d7e9ad498dce760d&scene=21#wechat_redirect" imgdata="null" imgurl="" linktype="text" tab="innerlink" target="_blank" textvalue=""><span class="js_jump_icon h5_image_link" data-positionback="static" style="outline: 0px;max-width: 100%;line-height: 0;vertical-align: bottom;user-select: none;box-sizing: border-box !important;overflow-wrap: break-word !important;"><img class="rich_pages wxw-img" data-backh="129" data-backw="578" data-cropselx1="0" data-cropselx2="578" data-cropsely1="0" data-cropsely2="128" data-ratio="0.22282608695652173" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/lnBicB8p160bj0GhAkog2YoP3YSDNHZicn4EnOEYealwq8Nm7MV0ZFm5ScOmQtXZxrWicGEsTiaRsWiazP25icZUlrxg/640?wx_fmt=png" data-type="png" data-w="2208" style="outline: 0px;border-width: 0px;border-style: initial;border-color: initial;display: initial;width: 578px;box-sizing: border-box !important;overflow-wrap: break-word !important;visibility: visible !important;height: 129px;"/></span></a></p><p style="margin-right: 8px;margin-left: 8px;outline: 0px;max-width: 100%;text-align: center;line-height: 2em;box-sizing: border-box !important;overflow-wrap: break-word !important;"><br data-filtered="filtered" style="outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;"/></p></section><section powered-by="xiumi.us" style="margin-top: 10px;margin-bottom: 10px;white-space: normal;outline: 0px;max-width: 100%;font-size: 15px;letter-spacing: 2px;color: rgb(121, 120, 117);font-family: Optima-Regular, PingFangTC-light;background-color: rgb(255, 255, 255);text-align: center;box-sizing: border-box !important;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box !important;overflow-wrap: break-word !important;"><img class="rich_pages wxw-img" data-backh="324" data-backw="550" data-cropselx1="0" data-cropselx2="578" data-cropsely1="0" data-cropsely2="340" data-fileid="100039599" data-ratio="0.5890909090909091" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/lnBicB8p160ZI7CU2RZZW95psZeEfmBlM2DBAuXpxjRtyL4lNjeLfABJaHMxV1dick4LVfvdjcrHhvbIicUV8L2Yg/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1" data-type="jpeg" data-w="550" style="vertical-align: middle;outline: 0px;box-sizing: border-box;width: 100%;display: initial;overflow-wrap: break-word !important;visibility: visible !important;height: auto;" width="550px"/></section></section><section powered-by="xiumi.us" style="margin-top: 10px;margin-bottom: 10px;white-space: normal;outline: 0px;max-width: 100%;font-size: 15px;letter-spacing: 2px;color: rgb(121, 120, 117);font-family: Optima-Regular, PingFangTC-light;background-color: rgb(255, 255, 255);text-align: right;box-sizing: border-box !important;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box !important;overflow-wrap: break-word !important;"><strong style="outline: 0px;max-width: 100%;color: rgb(56, 56, 56);font-size: 13px;box-sizing: border-box !important;overflow-wrap: break-word !important;">点个<span style="margin-right: 3px;margin-left: 3px;padding: 1px 3px;outline: 0px;max-width: 100%;background-color: rgb(171, 224, 225);border-radius: 2px;box-sizing: border-box !important;overflow-wrap: break-word !important;">“在看”</span>支持下小天吧~</strong></section><img class="rich_pages wxw-img" data-fileid="100039603" data-ratio="0.5691057" data-src="https://mmbiz.qpic.cn/mmbiz_png/lnBicB8p160ZKofw2MiaTPTj2jWV8ulkt9tuMtGcywyjiahZzp8UtYg3Wr6T1H0kDz6YKRYBqmZQfEDX0Dz5ib7oBw/640?wx_fmt=png&wxfrom=5&wx_lazy=1&wx_co=1" data-type="png" data-w="123" style="vertical-align: middle;outline: 0px;box-sizing: border-box;display: initial;overflow-wrap: break-word !important;visibility: visible !important;width: 33.6875px !important;" width="33.6875px"/></section><p><br/></p><p style="display: none;"><mp-style-type data-value="3"/></p></div>
个人中心
我是园区
退出
